Cachexia, Gastric Adenocarcinoma, Gastric Cancer, Malnutrition
Conditions
Keywords
gastric cancer, bioelectrical impedance analysis, body composition, nutritional status, malnutrition, cachexia, multimodal treatment, tumor regression grade
Brief summary
The aim of this single-arm prospective, multicenter, cross-sectional study is to evaluate the nutritional status and body composition on tumor regression grade with bioelectrical impedance analysis in gastric cancer patients undergoing multimodal treatment. Results of this study will reveal whether nutritional status and body composition assessment based on bioelectrical impedance analysis will become a validated and objective tool to support clinical decisions in gastric cancer patients undergoing multimodal treatment.
Detailed description
Up to 20% of gastric cancer patients experience unintentional loss of their pretreatment body weight. Malnutrition contributes to increased morbidity, higher risk of perioperative complications and systemic toxicity. A standardized approach to evaluate the nutritional status of gastric cancer patients is yet to be established. Bioelectrical impedance analysis is a non-invasive technique estimating changes in body composition over time. 125 patients with locally advanced gastric adenocarcinoma scheduled for multimodal treatment will be included in the study. Four consecutive nutritional status assessments will be performed throughout the treatment.
Interventions
OTHERObservational Survey
Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
Sponsors
Erasmus Medical Center
Ohio State University
Poznan University of Medical Sciences
Jagiellonian University
Medical University of Lublin
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Histologically confirmed gastric adenocarcinoma (or undifferentiated carcinoma) 3. Stage II - III disease (cT2 cN+ and cT3-T4 cN+/-) based on the 8th edition of TNM classification 4. Qualification for multimodal treatment by the decision of the multidisciplinary tumor board
Exclusion criteria
1. Early gastric cancer (cT1N0-3M0) scheduled for endoscopic treatment by multidisciplinary team 2. Gastric stump carcinoma 3. Distant metastasis 4. Upfront surgery 5. Other malignancies 6. Contraindications to bioelectrical impedance analysis (e.g., implanted cardiac devices, metal implants or pregnancy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Regression Grade | Up to 2-4 weeks after the surgery | determined using the Becker criteria (1- complete response, 2 - good response, 3 - partial response, 4 - no response) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neoadjuvant Chemotherapy Toxicity | From date of inclusion up to 1-3 months after the date of the first neoadjuvant chemotherapy cycle | evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) criteria (version 5.0) |
| Postoperative Complications | From date of surgery, assessed up to 90 days | Assessed by the Comprehensive Complication Index (CCI). Min-Max values (0-100), higher scores mean a worse outcome |
| Overall Survival | From from the date of surgery to the date of patient death or the date of the last follow-up - up to 10 years | Overall survival analysis will determine whether bioelectrical impedance analysis is a prognostic factor in advanced gastric cancer patients |
| Quality of Life score | From date of inclusion through study completion - an average of 3 years | Assessment based on The European Organization for Research and Treatment of Cancer quality of life, gastric-cancer specific questionnaire(EORTC QLQ - STO22). Min-Max value (1-7); higher scores mean a better outcome |
Countries
Poland
Contacts
Primary ContactZuzanna Pelc, PhD
Backup ContactKarol Rawicz-Pruszyński, Professor
Outcome results
None listed